Uttar Pradesh Passes Pharmaceutical & Medical Devices Industry Policy, 2023   

The government of Uttar Pradesh has cleared the Pharmaceutical and Medical devices Industry Policy, 2023 to ensure timely service delivery and permits bound clearances.'¯ 

The government of Uttar Pradesh has passed Pharmaceutical and Medical Devices Industry Policy 2023, in which a single window clearance process is established. The policy is now directly under the control of the Chief Minister's office. Processes include time-bound clearances, pre-consultation, project plans, technical advisory among others.'¯ 

The State has issued this single window clearance system policy to promote seamless and easy business processes. The Chief Minister's office now directly clears the processes such as marketing activities, pharma parks incentives, manufacturing units, and startup support.'¯ 

The goal of the strategy is to revitalise the State's pharmaceutical and medical device sector. This can be done by fostering domestic manufacturing, stimulating research and development, and expanding access to high-quality, reasonably priced medications for the population. The policy's objective is to create an environment that will support the expansion of the pharmaceutical industry.'¯ '¯ '¯ 

It also aims to build a robust ecosystem for research and development. The focus of the State is to mainly attract investments so that it can provide good incentives for subsidies and land allocation to set up manufacturing units.'¯ '¯ 

In the pharmaceutical and medical device industries, 217 businesses have proposed to invest approximately INR 28,500 Cr. Nearly 57,000 new jobs are anticipated to be created due to these investments. '¯ 

As part of creating time-bound clearances, the regulations will ensure prompt delivery of services, clearances, licences, and permits. 

The government will also establish the Uttar Pradesh Pharmaceutical Development Cell (UPPDC) as a technical advisory organisation. 

The Food and Drug Administration (FSDA) will appoint a nodal officer to assist investors. It will make it easier to get the pollution No Objection Certificate (NOC) and other licences needed to build pharmaceutical factories. To assess the project's viability, the team will examine the project data and the building plan provided by the investors. Following a thorough review of the dossier, an investor will receive a Letter of Comfort. 

To monitor the development of the policy and scheme implementation, an empowered committee will be there, chaired by the Chief Secretary. Additionally, it would have the authority to approve requests for large-scale projects (more than INR 100 Cr capital investment projects).'¯